Radiopharm Theranostics Limited cash flow statement RADX
In fiscal 2025, which ended Jun 30, 2025, Radiopharm Theranostics Limited used $36.6 million of cash from operations.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2025
Jun 30, 2025
|
|---|---|
| Operating | |
| Operating cash flow |
-37
|
| Investing | |
| Investing cash flow |
2
|
| Financing | |
| Financing cash flow |
45
|
| Change in cash | |
| Effect of exchange rate |
-0
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RADX (Nasdaq), RDPTF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Carlton Vic
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1949257
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.